Trials of a Medicine Maker
December 31, 2018
Where's this variability coming from? Time to investigate...
0 min read
2018
Back to Basics
November 16, 2018
David Walker, Executive Director of the Center for Biodefense and Emerging Infectious Diseases
0 min read
A Winning Bid
November 14, 2018
Founded in 1998, Emergent BioSolutions has gone on to become a multinational biopharma company – despite working in some difficult therapeutic areas, including biodefense.
0 min read
The Intersection of Infection and Biodefense
November 14, 2018
Marcus Horwitz’s primary focus is on infectious diseases, but a number of pathogens he has studied led him into the realm of bioterrorism. Recently, Horwitz and his team has developed a single vector vaccine platform that could offer protection against tularemia, anthrax, plague, and melioidosis – all considered significant bioterrorism threats.
0 min read
Rising to the Challenge
November 14, 2018
Biodefense is not just about offering protection from bioterror attacks; it’s also about being prepared for emerging infectious diseases.
0 min read
Easing Ion-Exchange Chromatography
November 14, 2018
Why salt-tolerant resins make for “happier” biomolecules with better binding.
0 min read
Discovery & Development
Business Practice
Contract Development Services
Trends & Forecasts
Contract Manufacturing Services
Changing Mindsets
November 14, 2018
Sitting Down With... Vivek Sharma, CEO of Piramal Pharma Solutions.
0 min read
The Winning Strategy for Start-Ups
November 14, 2018
Business academics have been trying to uncover empirical evidence around how financing decisions are linked with technology. After all, the business of making biopharmaceuticals is expensive – so the more data you have to back up decisions, the better.
0 min read
The New Antibody Formats on the Block
November 14, 2018
More complex alternatives to monoclonal antibodies are demanding innovation from manufacturing and purification techniques.
0 min read
